11/7/2023 | HY | Belgium’s UCB offers 5.2% senior notes in unrated retail offer
|
2/1/2022 | BK | UCB signs $800 million term loan for Zogenix acquisition
|
1/19/2022 | BK | UCB plans $800 million term loan for Zogenix purchase
|
10/10/2019 | BK | UCB to use bank term loans for Ra Pharmaceuticals purchase
|
1/28/2016 | EULM | UCB to redeem €300 million in subordinated securities on March 18
|
10/1/2009 | CV | UCB greenshoe fully exercised, raising convertibles to €500 million
|
9/30/2009 | CV | JPMorgan remains top U.S. market convertibles underwriter year to date
|
9/30/2009 | CV | New Issue: UCB prices upsized €450 million six-year convertibles to yield 4.5%, up 35%
|
9/30/2009 | CV | Market Commentary: Convertibles steady at quarter-end; CIT, D.R. Horton lower; Saks, Six Flags up: UAL on tap
|
10/27/2006 | BT | UCB kept at neutral by Merrill
|
10/11/2006 | BT | S&P: Pharmaceutical sales growth spurs mergers
|
9/27/2006 | BT | UCB at neutral by Merrill
|
9/26/2006 | BT | UCB: R&D day a chance to provide update on all programs
|
9/26/2006 | BT | Immunomedics, UCB suspend epratuzumab trials due to manufacturing concerns
|
9/25/2006 | BT | UCB at neutral by Merrill
|
9/25/2006 | BT | UCB, Sanofi to co-promote antihistamine Xyza in United States
|
9/25/2006 | BT | UCB makes offer for Schwartz Pharma
|
9/7/2006 | BT | Crucell signs European STAR licensing agreement
|
8/23/2006 | BT | UCB gets FDA approval to market Keppra to treat adolescent seizures
|
8/21/2006 | BT | Verus, UCB to commercialize allergy treatment Twinject in Europe
|
8/18/2006 | BT | UCB's Keppra gets key approval to treat newly diagnosed epilepsy patients
|
8/2/2006 | BT | UCB's Keppra gets FDA approval
|
7/31/2006 | BT | UCB downgraded to neutral by Merrill
|
7/27/2006 | BT | UCB submits New Drug Application for Xyzal
|
7/27/2006 | BT | Merrill rates UCB at buy
|
7/18/2006 | BT | Merrill rates UCB at buy
|
7/18/2006 | BT | UCB phase 2 study of Cimzia in psoriasis meets primary endpoints
|
7/3/2006 | BT | UCB receives European OK for use of Keppra as monotherapy for epilepsy
|
5/25/2006 | BT | Merrill keeps PDL at buy
|
5/24/2006 | BT | UCB completes mutual recognition procedure for Equasym XL
|
5/23/2006 | BT | UCB rated at buy by Merrill
|
5/22/2006 | BT | UCB says monthly Cimzia dose effective for Crohn's disease
|
5/15/2006 | BT | UCB at buy by Merrill
|
5/15/2006 | BT | UCB's Keppra approved by European Commission for juvenile epilepsy
|
5/10/2006 | BT | Immunomedics licenses developing, marketing rights for epratuzumab to UCB
|
5/10/2006 | BT | Merrill keeps UCB at buy
|
4/28/2006 | BT | UCB submits marketing application in Europe for Cimziatm for Crohn's disease
|
4/26/2006 | BT | UCB's Keppra receives two regulatory approvals for use in epilepsy
|
4/24/2006 | BT | UCB transfers sales, marketing rights of Corifeo; Recordati pays €10 million
|
3/15/2006 | BT | Merrill retains UCB at buy
|
3/14/2006 | BT | Merrill keeps UCB at buy
|
3/2/2006 | BT | UCB submits Biologics License Application to FDA for new treatment in Crohn's disease
|
2/23/2006 | BT | UCB reiterated at buy by Merrill
|
2/23/2006 | BT | Sepracor licenses antihistamine patents to UCB
|
2/3/2006 | BT | UCB receives positive regulatory opinions for seizure treatment
|
1/26/2006 | BT | Sareum, UCB collaborate on cancer drug discovery
|
1/19/2006 | BT | Praecis, UCB suspend production of Plenaxis ingredients
|
1/18/2006 | BT | UCB Pharma licenses mastocytosis drug Gastrocrom to Azur Pharma
|
1/17/2006 | BT | Lonza acquires the bioproducts manufacturing division of UCB
|
12/19/2005 | BT | Merrill reiterates UCB at buy
|
12/13/2005 | BT | UCB reiterated by Merrill at buy
|
12/8/2005 | BT | UCB launches Xyrem in Germany for cataplexy
|
12/6/2005 | BT | UCB reports one in four epilepsy patients free of seizures with Keppra
|
11/17/2005 | BT | Actelion, UCB restructure Zavesca license agreement
|
10/31/2005 | BT | UCB's Cimzia alleviates Crohn's Disease symptoms in phase-3 trial
|
10/27/2005 | BT | Merrill retains buy for UCB
|
10/27/2005 | BT | UCB Pharma files supplemental new drug application for Keppra
|
10/20/2005 | BT | Merrill Lynch retains UCB at buy
|
10/19/2005 | BT | Merrill Lynch maintains UCB at buy
|
10/18/2005 | BT | Merrill Lynch maintains UCB at buy
|
9/15/2005 | BT | UCB retained by Merrill Lynch at buy
|
8/26/2005 | BT | UCB sells Celltech for €27.5 million
|
7/28/2005 | BT | UCB estimates upped by Merrill Lynch
|
7/27/2005 | BT | UCB price target upped by Merrill Lynch
|
7/20/2005 | BT | UCB maintained by Merrill Lynch at buy
|
7/13/2005 | BT | Serono may progress while Tysabri slows, Merrill bio/pharma earnings preview says
|